Clinical trial
Combination Chemotherapy Plus Oblimersen in Treating Patients With Previously…
NCT00017251 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00017251 |
|---|---|
| Title | Combination Chemotherapy Plus Oblimersen in Treating Patients With Previously Untreated Extensive-Stage Small Cell Lung Cancer |
| Official title | A Phase I Study Of Genasense, A Bcl-2 Antisense Oligonucleotide, Combined With Carboplatin And Etoposide In Patients With Small Cell Lung Cancer |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Extensive Stage Small Cell Lung Cancer |
| Intervention type | Biological, Drug, Other |
| Interventions | oblimersen sodium, carboplatin, etoposide, pharmacological study, laboratory biomarker analysis |
| Enrollment | 12 |
| Start date | Apr 1, 2001 |
| Primary completion | Jan 1, 2004 |
| First posted | Jan 27, 2003 |
| Last update posted | Jan 24, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: